Performance Evaluation of a Chemiluminescence Microparticle Immunoassay for CK-MB
Zhi-yuan Lin,Yi-zhen Fang,Hong-wei Jin,Hua-yue Lin,Zhang Dai,Qing Luo,Hong-wei Li,Yan-ling Lin,Shui-zhen Huang,Lei Gao,Fei-hai Xu,Zhong-ying Zhang
DOI: https://doi.org/10.1002/jcla.22426
IF: 3.124
2018-01-01
Journal of Clinical Laboratory Analysis
Abstract:BackgroundTo verify and evaluate the performance characteristics of a creatine kinase phosphokinase isoenzymes MB (CK‐MB) assay kit, which produced by Xiamen Innodx Biotech Co. Ltd.MethodsEvaluation was carried out according to “Guidelines for principle of analysis performance evaluation of in vitro diagnostic reagent.” The performance parameters included detection limit, linearity range, reportable range, recovery test, precision verification, interference test, cross‐reactivity, matrix effect, and method comparison.ResultsThe detection limit was 0.1 ng/mL. The assay had clinical linearity over range of 0.1 ng/mL‐500 ng/mL. Reportable range was from 0.1 ng/mL to 1000 ng/mL. The average percent of recovery was 99.66%. The coefficient of variation (CV) for within‐run and between‐run of low CK‐MB sample was 5.55% and 6.16%, respectively. As for high‐level sample, it was 7.88% and 7.80%. In medical decision level, the relative deviation (Bias) of all interference tests was lower than 15%. When the sample had mild‐hemolysis; hemoglobin ≤15 g/L; triglyceride ≤17 mmol/L; bilirubin ≤427.5 μmol/L; rheumatoid factor ≤206U/mL, there was no significant interference to be found. Moreover, assay kit had no cross‐reaction with CK‐MM and CK‐BB. At last, total diagnostic accuracy of kit was 93.24%, when compared with refer kit.ConclusionOverall the results of the verification study indicated the performance of kit is met the requirements of the clinical test.